SiVEC Biotechnologies aims to revolutionize the delivery of nucleic acids and other biologically active cargo to enable the development of safer and more effective therapies.


SiVEC Biotechnologies is an R&D company based in Fort Collins, CO at the Research Innovation Center. We have developed a platform technology for the manufacture and delivery of nucleic acids and we hold a portfolio of intellectual property with relevance to human and animal health. The collaborative spirit and diversity in scientific expertise of our team supports the rigorous science which is at the core of our company. 


To provide a delivery platform that will enable biopharma to bring innovative nucleic acid and gene therapies to market. 


SiVEC is a biopharma partnering company with a mission to provide a novel
platform that will support the translation of innovative nucleic acid and gene
therapies from the R&D phase to the clinic and finally into the market. To date, we
have acquired nearly $4 million in non-dilutive funding, which has
supported the development of our bacterial delivery system, which we – as a proof
of concept – are currently using as a vehicle for delivery of an siRNA-based
influenza antiviral in preclinical development. We have also taken an aggressive
approach to protecting our IP and have a strong patent portfolio.


Lyndsey Linke, PhD, ME



Dr. Linke is the CEO and company co-founder. She has secured over $4 million in grants and sponsored research for SiVEC Biotechnologies and brings over 15 years of scientific experience related to the R&D of novel therapeutics, antivirals, and diagnostic tests. Dr. Linke is first named inventor on four pending patents related to the SiVEC delivery platform and antiviral technology. She has a PhD in Infectious Disease Epidemiology and a Master of Engineering in Biomedical Engineering from Colorado State University.

Darcy Mora, MS

VP of Operations &


Ms. Darcy Mora is the Vice President of Operations and company co-founder. She has over 12 years of experience with infectious disease and vaccine R&D  including serving as a lead developer for more than ten global wildlife vaccines. Ms. Mora is an inventor on three pending patents related to SiVEC's delivery platform and antiviral technology. Ms. Mora received her Masters of Science in Veterinary Epidemiology and a Bachelor of Science in Biochemistry from Colorado State University.

Ash Williams, PhD

Director of Research & Development

Dr. Williams is the Director of Research and Development. He has over 15 years of experience studying the molecular biology and genetics of Escherichia coli and has extensive research experience related to RNA interference, host-pathogen interactions, immune DNA sensing, and systemic inflammatory responses. Dr. Williams received his Bachelor of Science and Ph.D. in Microbiology from Indiana University and completed post-doctoral fellowships at Harvard University and the University of Southern California.


Danny Goovaerts, DVM, MS: Dr. Goovaerts has decades of experience in vaccine R&D for both agriculture and companion animals. His career has included roles in R&D management, regulatory affairs, pathology, production, animal services and veterinary care. Dr. Goovaerts was Director of R&D at Intervet (Merck) prior to starting his own consulting firm. As a consultant he is involved with companies located all over the world providing insight on a range of animal health topics from manufacturing facility design to R&D strategy for veterinary vaccines. As a valued Scientific Advisor to SiVEC Biotechnologies, Dr. Goovaerts provides expertise on the poultry biologics market, regulatory considerations for different countries, scientific research approach, business strategy, and more. 

John Wyckoff, PhD: Dr. Wyckoff is an Immuologist with over 33 years' scientific research experience in both academia and industry. Having served in a director/manager position for veterinary vaccine R&D for three of the largest global animal health companies, Dr. Wyckoff has a deep understanding of diverse animal health markets and company interests. As the current Director of BioMARC, a contract development and manufacturing organization for biologics, Dr. Wyckoff is aware of many manufacturing and regulatory considerations that are important to SiVEC's commercialization efforts. In his role as a Scientific Advisor to SiVEC Biotechnologies, Dr. Wyckoff is a wonderful resource for many topics, including study design, licensing requirements, global animal health product markets, and partnering opportunities. 

Danny Goovaerts Headshot.jpg
John Wyckoff III.jpg


Sibylle Hauser, MBA: Business and finance strategy

Terry Opgenorth, PhD, MS; Antiviral research, pharmaceutical R&D 

Heidi Nelson-Keherly, PhD: Preclinical optimization & regulatory affairs

Jeff Wilusz, PhD: Scientific strategy, RNA stability & decay